ESMO 2024: adding Metformin to ADT for patients with mHSPC from STAMPEDE trial

[Maxone73]

My take is that there is no advantage adding metformin in mHSPC when it's low volume. It looks like there is statistically significant advantage in case of high volume, but still needs to be confirmed. (T_A will correct me if I am wrong)

We will need a further trial designed for high volume patients probably.

Interestingly, there was a consistent improvement in metabolic parameters which suggests that metformin could play a role in enhancing the quality of life and long-term health of patients undergoing ADT.

urotoday.com/conference-hig...

[JohnInTheMiddle]

Super thanks Max for your commentary on addition of metformin to a therapy regime for someone with mHSPC. I do take some metformin; because I'm borderline and have to work at keeping my cells insulin sensitive. At DX I was also high volume. My sense is that sugar control is really important for many people with cancer or not.

[Seasid in reply to JohnInTheMiddle]

It is proven by research that metformin is beneficial if you have an aggressive prostate cancer and that is enough for me to use it.